+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Exosome Diagnostic and Therapeutic Market By Application (Diagnostic, Therapeutic), By Product (Instrument, Reagent, Software), By End User (Cancer Institute, Hospital, Diagnostic Center, Others): Global Opportunity Analysis and Industry Forecast, 2021-2030

  • PDF Icon

    Report

  • 110 Pages
  • August 2023
  • Region: Global
  • Allied Market Research
  • ID: 5640508
The global exosome diagnostic and therapeutic market was valued at $224.3 million in 2020, and is projected to reach $2.92 billion by 2030, registering a CAGR of 29.4% from 2021 to 2030. Exosomes are small extracellular vesicles present in various body fluids, such as saliva, urine, blood, and breast milk. These vesicles play an important role in intercellular communication processes and have specific composition of proteins, lipids, messenger ribonucleic acid (mRNA), and micro ribonucleic acid (RNA). Presently, exosomes have great potential to be utilized for drug delivery and a biomarker for the diagnosis and testing of various diseases. Moreover, exosomes offer an alternative pathway for invasive biopsy used in the diagnosis and management of different types of cancer. The global exosome diagnostic and therapeutic market is driven by increase in prevalence of cancer, growth in initiatives implemented by the government and non-government associations, rise in health awareness, technological advancements in exosomes isolation, surge in analytical procedures, and increase in innovative and advanced applications of exosomes. However, stringent government regulations for the approval of exosomes diagnostic and therapeutic products and lack of awareness about the applications of exosomes restrict the market growth.

Furthermore, the developing countries, such as China and India are expected to provide huge growth opportunities to this market. The exosomes diagnostic and therapeutic market is segmented on the basis of application, product, end user, and region. As per the application, it is bifurcated into diagnostic and therapeutic applications. By the product, it is classified into instrument, reagents, and software. Depending on end user, it is segmented into cancer institute, hospitals, diagnostic centers, and others (medical universities and not-for-profit organizations). Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America dominated the market in 2020, and is expected to maintain its dominance throughout the forecast period, due to factors, such as increase in R&D investments, technological advancement in the exosomes isolation procedures, and rise in incidence of cancer. In addition, Asia-Pacific is expected to emerge as the area with maximum growth potential due to the increase in focus of key players on developing countries, rise in clinical research & trial outsourcing, growth in awareness & focus on health of the people, and surge in incidence of cancer & other chronic diseases.
The report provides a comprehensive analysis of the key players operating in the exosome diagnostics and therapeutic market, including Aethlon Medical, Inc. (U.S.), Exosome Diagnostics Inc. (U.S.), NanoSomix Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Malvern Instruments Ltd. (UK), System Biosciences Inc. (U.S.), NX Pharmagen (U.S.), Sistemic Inc. (UK), Capricor Therapeutics (U.S.), and Exiqon A/S (Denmark).

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the exosome diagnostic and therapeutic market analysis from 2020 to 2030 to identify the prevailing exosome diagnostic and therapeutic market opportunity.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the exosome diagnostic and therapeutic market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global exosome diagnostic and therapeutic market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly update (only available with the purchase of an enterprise license)
  • 5 additional company profiles of your choice, pre- or post-purchase, as a free update.
  • Free updated version (once released) with the purchase of a 1-5 or enterprise user license.
  • 16 analyst hours of support (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% free customization (in case the scope or segment of the report does not match your requirements, 20% is equivalent to 3 working days of free work, applicable once)
  • Free data pack (Excel version) with the purchase of a 1-5 or enterprise user license.
  • Free report update, if the report is 6-12 months old or older.
  • 24-hour priority response
  • Free industry updates and white papers.

Key Market Segments

By Application

  • Diagnostic
  • Therapeutic

By Product

  • Instrument
  • Reagent
  • Software

By End User

  • Cancer Institute
  • Hospital
  • Diagnostic Center
  • Others

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players

  • Thermo Fisher Scientific, Inc.
  • Malvern Instruments Ltd
  • NX Pharmagen, Inc.
  • Sistemic Ltd
  • Exosome Diagnostic, Inc.
  • Capricor Therapeutics, Inc.
  • NanoSomix, Inc
  • System Biosciences, Inc
  • Exiqon A/S
  • Aethlon Medical, Inc.

 

Please note:

  • Online Access price format is valid for 60 days access. Printing is not enabled.
  • PDF Single and Enterprise price formats enable printing.

 

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Low bargaining power of suppliers
3.3.2. Low threat of new entrants
3.3.3. Low threat of substitutes
3.3.4. Low intensity of rivalry
3.3.5. Low bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increase in prevalence of chronic diseases
3.4.1.2. Increase in prevalence of cancer
3.4.1.3. Rise in number of geriatric populations
3.4.2. Restraints
3.4.2.1. Lack of product approvals for exosome diagnostic and therapeutic technique
3.4.3. Opportunities
3.4.3.1. Rise in adoption of key strategies
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION
4.1. Overview
4.1.1. Market size and forecast
4.2. Diagnostic
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Therapeutic
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
CHAPTER 5: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT
5.1. Overview
5.1.1. Market size and forecast
5.2. Instrument
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Reagent
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Software
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
CHAPTER 6: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Cancer Institute
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Hospital
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Diagnostic Center
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
6.5. Others
6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast, by region
6.5.3. Market share analysis by country
CHAPTER 7: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. Market size and forecast, by Application
7.2.3. Market size and forecast, by Product
7.2.4. Market size and forecast, by End User
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Key market trends, growth factors and opportunities
7.2.5.1.2. Market size and forecast, by Application
7.2.5.1.3. Market size and forecast, by Product
7.2.5.1.4. Market size and forecast, by End User
7.2.5.2. Canada
7.2.5.2.1. Key market trends, growth factors and opportunities
7.2.5.2.2. Market size and forecast, by Application
7.2.5.2.3. Market size and forecast, by Product
7.2.5.2.4. Market size and forecast, by End User
7.2.5.3. Mexico
7.2.5.3.1. Key market trends, growth factors and opportunities
7.2.5.3.2. Market size and forecast, by Application
7.2.5.3.3. Market size and forecast, by Product
7.2.5.3.4. Market size and forecast, by End User
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Market size and forecast, by Application
7.3.3. Market size and forecast, by Product
7.3.4. Market size and forecast, by End User
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Key market trends, growth factors and opportunities
7.3.5.1.2. Market size and forecast, by Application
7.3.5.1.3. Market size and forecast, by Product
7.3.5.1.4. Market size and forecast, by End User
7.3.5.2. France
7.3.5.2.1. Key market trends, growth factors and opportunities
7.3.5.2.2. Market size and forecast, by Application
7.3.5.2.3. Market size and forecast, by Product
7.3.5.2.4. Market size and forecast, by End User
7.3.5.3. U.K.
7.3.5.3.1. Key market trends, growth factors and opportunities
7.3.5.3.2. Market size and forecast, by Application
7.3.5.3.3. Market size and forecast, by Product
7.3.5.3.4. Market size and forecast, by End User
7.3.5.4. Italy
7.3.5.4.1. Key market trends, growth factors and opportunities
7.3.5.4.2. Market size and forecast, by Application
7.3.5.4.3. Market size and forecast, by Product
7.3.5.4.4. Market size and forecast, by End User
7.3.5.5. Spain
7.3.5.5.1. Key market trends, growth factors and opportunities
7.3.5.5.2. Market size and forecast, by Application
7.3.5.5.3. Market size and forecast, by Product
7.3.5.5.4. Market size and forecast, by End User
7.3.5.6. Rest of Europe
7.3.5.6.1. Key market trends, growth factors and opportunities
7.3.5.6.2. Market size and forecast, by Application
7.3.5.6.3. Market size and forecast, by Product
7.3.5.6.4. Market size and forecast, by End User
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Market size and forecast, by Application
7.4.3. Market size and forecast, by Product
7.4.4. Market size and forecast, by End User
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Key market trends, growth factors and opportunities
7.4.5.1.2. Market size and forecast, by Application
7.4.5.1.3. Market size and forecast, by Product
7.4.5.1.4. Market size and forecast, by End User
7.4.5.2. China
7.4.5.2.1. Key market trends, growth factors and opportunities
7.4.5.2.2. Market size and forecast, by Application
7.4.5.2.3. Market size and forecast, by Product
7.4.5.2.4. Market size and forecast, by End User
7.4.5.3. Rest of Asia-Pacific
7.4.5.3.1. Key market trends, growth factors and opportunities
7.4.5.3.2. Market size and forecast, by Application
7.4.5.3.3. Market size and forecast, by Product
7.4.5.3.4. Market size and forecast, by End User
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by Application
7.5.3. Market size and forecast, by Product
7.5.4. Market size and forecast, by End User
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Key market trends, growth factors and opportunities
7.5.5.1.2. Market size and forecast, by Application
7.5.5.1.3. Market size and forecast, by Product
7.5.5.1.4. Market size and forecast, by End User
7.5.5.2. Saudi Arabia
7.5.5.2.1. Key market trends, growth factors and opportunities
7.5.5.2.2. Market size and forecast, by Application
7.5.5.2.3. Market size and forecast, by Product
7.5.5.2.4. Market size and forecast, by End User
7.5.5.3. South Africa
7.5.5.3.1. Key market trends, growth factors and opportunities
7.5.5.3.2. Market size and forecast, by Application
7.5.5.3.3. Market size and forecast, by Product
7.5.5.3.4. Market size and forecast, by End User
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Key market trends, growth factors and opportunities
7.5.5.4.2. Market size and forecast, by Application
7.5.5.4.3. Market size and forecast, by Product
7.5.5.4.4. Market size and forecast, by End User
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Players
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2020
CHAPTER 9: COMPANY PROFILES
9.1. Aethlon Medical, Inc.
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Key strategic moves and developments
9.2. Exosome Diagnostic, Inc.
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Key strategic moves and developments
9.3. NanoSomix, Inc
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.4. Thermo Fisher Scientific, Inc.
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.5. Malvern Instruments Ltd
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.6. System Biosciences, Inc
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.7. NX Pharmagen, Inc.
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.8. Sistemic Ltd
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.9. Capricor Therapeutics, Inc.
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.10. Exiqon A/S
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
List of Tables
Table 01. Global Exosome Diagnostic and Therapeutic Market, by Application, 2020-2030 ($Million)
Table 02. Exosome Diagnostic and Therapeutic Market for Diagnostic, by Region, 2020-2030 ($Million)
Table 03. Exosome Diagnostic and Therapeutic Market for Therapeutic, by Region, 2020-2030 ($Million)
Table 04. Global Exosome Diagnostic and Therapeutic Market, by Product, 2020-2030 ($Million)
Table 05. Exosome Diagnostic and Therapeutic Market for Instrument, by Region, 2020-2030 ($Million)
Table 06. Exosome Diagnostic and Therapeutic Market for Reagent, by Region, 2020-2030 ($Million)
Table 07. Exosome Diagnostic and Therapeutic Market for Software, by Region, 2020-2030 ($Million)
Table 08. Global Exosome Diagnostic and Therapeutic Market, by End-user, 2020-2030 ($Million)
Table 09. Exosome Diagnostic and Therapeutic Market for Cancer Institute, by Region, 2020-2030 ($Million)
Table 10. Exosome Diagnostic and Therapeutic Market for Hospital, by Region, 2020-2030 ($Million)
Table 11. Exosome Diagnostic and Therapeutic Market for Diagnostic Center, by Region, 2020-2030 ($Million)
Table 12. Exosome Diagnostic and Therapeutic Market for Others, by Region, 2020-2030 ($Million)
Table 13. Exosome Diagnostic and Therapeutic Market, by Region, 2020-2030 ($Million)
Table 14. North America Exosome Diagnostic and Therapeutic Market, by Application, 2020-2030 ($Million)
Table 15. North America Exosome Diagnostic and Therapeutic Market, by Product, 2020-2030 ($Million)
Table 16. North America Exosome Diagnostic and Therapeutic Market, by End-user, 2020-2030 ($Million)
Table 17. North America Exosome Diagnostic and Therapeutic Market, by Country, 2020-2030 ($Million)
Table 18. U.S. Exosome Diagnostic and Therapeutic Market, by Application, 2020-2030 ($Million)
Table 19. U.S. Exosome Diagnostic and Therapeutic Market, by Product, 2020-2030 ($Million)
Table 20. U.S. Exosome Diagnostic and Therapeutic Market, by End-user, 2020-2030 ($Million)
Table 21. Canada Exosome Diagnostic and Therapeutic Market, by Application, 2020-2030 ($Million)
Table 22. Canada Exosome Diagnostic and Therapeutic Market, by Product, 2020-2030 ($Million)
Table 23. Canada Exosome Diagnostic and Therapeutic Market, by End-user, 2020-2030 ($Million)
Table 24. Mexico Exosome Diagnostic and Therapeutic Market, by Application, 2020-2030 ($Million)
Table 25. Mexico Exosome Diagnostic and Therapeutic Market, by Product, 2020-2030 ($Million)
Table 26. Mexico Exosome Diagnostic and Therapeutic Market, by End-user, 2020-2030 ($Million)
Table 27. Europe Exosome Diagnostic and Therapeutic Market, by Application, 2020-2030 ($Million)
Table 28. Europe Exosome Diagnostic and Therapeutic Market, by Product, 2020-2030 ($Million)
Table 29. Europe Exosome Diagnostic and Therapeutic Market, by End-user, 2020-2030 ($Million)
Table 30. Europe Exosome Diagnostic and Therapeutic Market, by Country, 2020-2030 ($Million)
Table 31. Germany Exosome Diagnostic and Therapeutic Market, by Application, 2020-2030 ($Million)
Table 32. Germany Exosome Diagnostic and Therapeutic Market, by Product, 2020-2030 ($Million)
Table 33. Germany Exosome Diagnostic and Therapeutic Market, by End-user, 2020-2030 ($Million)
Table 34. France Exosome Diagnostic and Therapeutic Market, by Application, 2020-2030 ($Million)
Table 35. France Exosome Diagnostic and Therapeutic Market, by Product, 2020-2030 ($Million)
Table 36. France Exosome Diagnostic and Therapeutic Market, by End-user, 2020-2030 ($Million)
Table 37. U.K. Exosome Diagnostic and Therapeutic Market, by Application, 2020-2030 ($Million)
Table 38. U.K. Exosome Diagnostic and Therapeutic Market, by Product, 2020-2030 ($Million)
Table 39. U.K. Exosome Diagnostic and Therapeutic Market, by End-user, 2020-2030 ($Million)
Table 40. Italy Exosome Diagnostic and Therapeutic Market, by Application, 2020-2030 ($Million)
Table 41. Italy Exosome Diagnostic and Therapeutic Market, by Product, 2020-2030 ($Million)
Table 42. Italy Exosome Diagnostic and Therapeutic Market, by End-user, 2020-2030 ($Million)
Table 43. Spain Exosome Diagnostic and Therapeutic Market, by Application, 2020-2030 ($Million)
Table 44. Spain Exosome Diagnostic and Therapeutic Market, by Product, 2020-2030 ($Million)
Table 45. Spain Exosome Diagnostic and Therapeutic Market, by End-user, 2020-2030 ($Million)
Table 46. Rest of Europe Exosome Diagnostic and Therapeutic Market, by Application, 2020-2030 ($Million)
Table 47. Rest of Europe Exosome Diagnostic and Therapeutic Market, by Product, 2020-2030 ($Million)
Table 48. Rest of Europe Exosome Diagnostic and Therapeutic Market, by End-user, 2020-2030 ($Million)
Table 49. Asia-Pacific Exosome Diagnostic and Therapeutic Market, by Application, 2020-2030 ($Million)
Table 50. Asia-Pacific Exosome Diagnostic and Therapeutic Market, by Product, 2020-2030 ($Million)
Table 51. Asia-Pacific Exosome Diagnostic and Therapeutic Market, by End-user, 2020-2030 ($Million)
Table 52. Asia-Pacific Exosome Diagnostic and Therapeutic Market, by Country, 2020-2030 ($Million)
Table 53. Japan Exosome Diagnostic and Therapeutic Market, by Application, 2020-2030 ($Million)
Table 54. Japan Exosome Diagnostic and Therapeutic Market, by Product, 2020-2030 ($Million)
Table 55. Japan Exosome Diagnostic and Therapeutic Market, by End-user, 2020-2030 ($Million)
Table 56. China Exosome Diagnostic and Therapeutic Market, by Application, 2020-2030 ($Million)
Table 57. China Exosome Diagnostic and Therapeutic Market, by Product, 2020-2030 ($Million)
Table 58. China Exosome Diagnostic and Therapeutic Market, by End-user, 2020-2030 ($Million)
Table 59. Rest of Asia-Pacific Exosome Diagnostic and Therapeutic Market, by Application, 2020-2030 ($Million)
Table 60. Rest of Asia-Pacific Exosome Diagnostic and Therapeutic Market, by Product, 2020-2030 ($Million)
Table 61. Rest of Asia-Pacific Exosome Diagnostic and Therapeutic Market, by End-user, 2020-2030 ($Million)
Table 62. LAMEA Exosome Diagnostic and Therapeutic Market, by Application, 2020-2030 ($Million)
Table 63. LAMEA Exosome Diagnostic and Therapeutic Market, by Product, 2020-2030 ($Million)
Table 64. LAMEA Exosome Diagnostic and Therapeutic Market, by End-user, 2020-2030 ($Million)
Table 65. LAMEA Exosome Diagnostic and Therapeutic Market, by Country, 2020-2030 ($Million)
Table 66. Brazil Exosome Diagnostic and Therapeutic Market, by Application, 2020-2030 ($Million)
Table 67. Brazil Exosome Diagnostic and Therapeutic Market, by Product, 2020-2030 ($Million)
Table 68. Brazil Exosome Diagnostic and Therapeutic Market, by End-user, 2020-2030 ($Million)
Table 69. Saudi Arabia Exosome Diagnostic and Therapeutic Market, by Application, 2020-2030 ($Million)
Table 70. Saudi Arabia Exosome Diagnostic and Therapeutic Market, by Product, 2020-2030 ($Million)
Table 71. Saudi Arabia Exosome Diagnostic and Therapeutic Market, by End-user, 2020-2030 ($Million)
Table 72. South Africa Exosome Diagnostic and Therapeutic Market, by Application, 2020-2030 ($Million)
Table 73. South Africa Exosome Diagnostic and Therapeutic Market, by Product, 2020-2030 ($Million)
Table 74. South Africa Exosome Diagnostic and Therapeutic Market, by End-user, 2020-2030 ($Million)
Table 75. Rest of LAMEA Exosome Diagnostic and Therapeutic Market, by Application, 2020-2030 ($Million)
Table 76. Rest of LAMEA Exosome Diagnostic and Therapeutic Market, by Product, 2020-2030 ($Million)
Table 77. Rest of LAMEA Exosome Diagnostic and Therapeutic Market, by End-user, 2020-2030 ($Million)
Table 78. Aethlon Medical, Inc.: Key Executives
Table 79. Aethlon Medical, Inc.: Company Snapshot
Table 80. Aethlon Medical, Inc.: Product Segments
Table 81. Aethlon Medical, Inc.: Product Portfolio
Table 82. Aethlon Medical, Inc.: Key Stratergies
Table 83. Exosome Diagnostic, Inc.: Key Executives
Table 84. Exosome Diagnostic, Inc.: Company Snapshot
Table 85. Exosome Diagnostic, Inc.: Product Segments
Table 86. Exosome Diagnostic, Inc.: Product Portfolio
Table 87. Exosome Diagnostic, Inc.: Key Stratergies
Table 88. Nanosomix, Inc.: Key Executives
Table 89. Nanosomix, Inc.: Company Snapshot
Table 90. Nanosomix, Inc.: Product Segments
Table 91. Nanosomix, Inc.: Product Portfolio
Table 92. Thermo Fisher Scientific, Inc.: Key Executives
Table 93. Thermo Fisher Scientific, Inc.: Company Snapshot
Table 94. Thermo Fisher Scientific, Inc.: Product Segments
Table 95. Thermo Fisher Scientific, Inc.: Product Portfolio
Table 96. Malvern Instruments Ltd.: Key Executives
Table 97. Malvern Instruments Ltd.: Company Snapshot
Table 98. Malvern Instruments Ltd.: Product Segments
Table 99. Malvern Instruments Ltd.: Product Portfolio
Table 100. System Biosciences, Inc.: Key Executives
Table 101. System Biosciences, Inc.: Company Snapshot
Table 102. System Biosciences, Inc.: Product Segments
Table 103. System Biosciences, Inc.: Service Segments
Table 104. System Biosciences, Inc.: Product Portfolio
Table 105. Nx Pharmagen, Inc.: Key Executives
Table 106. Nx Pharmagen, Inc.: Company Snapshot
Table 107. Nx Pharmagen, Inc.: Product Segments
Table 108. Nx Pharmagen, Inc.: Product Portfolio
Table 109. Sistemic Ltd.: Key Executives
Table 110. Sistemic Ltd.: Company Snapshot
Table 111. Sistemic Ltd.: Product Segments
Table 112. Sistemic Ltd.: Product Portfolio
Table 113. Capricor Therapeutics, Inc.: Key Executives
Table 114. Capricor Therapeutics, Inc.: Company Snapshot
Table 115. Capricor Therapeutics, Inc.: Service Segments
Table 116. Capricor Therapeutics, Inc.: Product Portfolio
Table 117. Exiqon A/S: Key Executives
Table 118. Exiqon A/S: Company Snapshot
Table 119. Exiqon A/S: Product Segments
Table 120. Exiqon A/S: Product Portfolio
List of Figures
Figure 01. Exosome Diagnostic and Therapeutic Market, 2020-2030
Figure 02. Segmentation of Exosome Diagnostic and Therapeutic Market, 2020-2030
Figure 03. Top Investment Pockets in Exosome Diagnostic and Therapeutic Market (2021-2030)
Figure 04. Low Bargaining Power of Suppliers
Figure 05. Low Threat of New Entrants
Figure 06. Low Threat of Substitutes
Figure 07. Low Intensity of Rivalry
Figure 08. Low Bargaining Power of Buyers
Figure 09. Global Exosome Diagnostic and Therapeutic Market:Drivers, Restraints and Opportunities
Figure 10. Exosome Diagnostic and Therapeutic Market, by Application, 2020 (%)
Figure 11. Comparative Share Analysis of Exosome Diagnostic and Therapeutic Market for Diagnostic, by Country 2020 and 2030 (%)
Figure 12. Comparative Share Analysis of Exosome Diagnostic and Therapeutic Market for Therapeutic, by Country 2020 and 2030 (%)
Figure 13. Exosome Diagnostic and Therapeutic Market, by Product, 2020 (%)
Figure 14. Comparative Share Analysis of Exosome Diagnostic and Therapeutic Market for Instrument, by Country 2020 and 2030 (%)
Figure 15. Comparative Share Analysis of Exosome Diagnostic and Therapeutic Market for Reagent, by Country 2020 and 2030 (%)
Figure 16. Comparative Share Analysis of Exosome Diagnostic and Therapeutic Market for Software, by Country 2020 and 2030 (%)
Figure 17. Exosome Diagnostic and Therapeutic Market, by End-user, 2020 (%)
Figure 18. Comparative Share Analysis of Exosome Diagnostic and Therapeutic Market for Cancer Institute, by Country 2020 and 2030 (%)
Figure 19. Comparative Share Analysis of Exosome Diagnostic and Therapeutic Market for Hospital, by Country 2020 and 2030 (%)
Figure 20. Comparative Share Analysis of Exosome Diagnostic and Therapeutic Market for Diagnostic Center, by Country 2020 and 2030 (%)
Figure 21. Comparative Share Analysis of Exosome Diagnostic and Therapeutic Market for Others, by Country 2020 and 2030 (%)
Figure 22. Exosome Diagnostic and Therapeutic Market by Region, 2020 (%)
Figure 23. U.S. Exosome Diagnostic and Therapeutic Market, 2020-2030 ($Million)
Figure 24. Canada Exosome Diagnostic and Therapeutic Market, 2020-2030 ($Million)
Figure 25. Mexico Exosome Diagnostic and Therapeutic Market, 2020-2030 ($Million)
Figure 26. Germany Exosome Diagnostic and Therapeutic Market, 2020-2030 ($Million)
Figure 27. France Exosome Diagnostic and Therapeutic Market, 2020-2030 ($Million)
Figure 28. U.K. Exosome Diagnostic and Therapeutic Market, 2020-2030 ($Million)
Figure 29. Italy Exosome Diagnostic and Therapeutic Market, 2020-2030 ($Million)
Figure 30. Spain Exosome Diagnostic and Therapeutic Market, 2020-2030 ($Million)
Figure 31. Rest of Europe Exosome Diagnostic and Therapeutic Market, 2020-2030 ($Million)
Figure 32. Japan Exosome Diagnostic and Therapeutic Market, 2020-2030 ($Million)
Figure 33. China Exosome Diagnostic and Therapeutic Market, 2020-2030 ($Million)
Figure 34. Rest of Asia-Pacific Exosome Diagnostic and Therapeutic Market, 2020-2030 ($Million)
Figure 35. Brazil Exosome Diagnostic and Therapeutic Market, 2020-2030 ($Million)
Figure 36. Saudi Arabia Exosome Diagnostic and Therapeutic Market, 2020-2030 ($Million)
Figure 37. South Africa Exosome Diagnostic and Therapeutic Market, 2020-2030 ($Million)
Figure 38. Rest of LAMEA Exosome Diagnostic and Therapeutic Market, 2020-2030 ($Million)
Figure 39. Top Winning Strategies, by Year
Figure 40. Top Winning Strategies, by Development
Figure 41. Top Winning Strategies, by Company
Figure 42. Product Mapping of Top 10 Players
Figure 43. Competitive Dashboard
Figure 44. Competitive Heatmap: Exosome Diagnostic and Therapeutic Market
Figure 45. Top Player Positioning, 2020
Figure 46. Thermo Fisher Scientific, Inc.: Net Revenue, 2019-2021 ($Million)
Figure 47. Thermo Fisher Scientific, Inc.: Revenue Share by Segment, 2021 (%)
Figure 48. Thermo Fisher Scientific, Inc.: Revenue Share by Region, 2021 (%)
Figure 49. Capricor Therapeutics, Inc.: Net Revenue, 2020-2022 ($Million)

Executive Summary

According to this report, the exosome diagnostic and therapeutic market was valued at $224.34 million in 2020, and is estimated to reach $2.9 billion by 2030, growing at a CAGR of 29.4% from 2021 to 2030. Exosomes applications are associated with immune responses, viral pathogenicity, pregnancy, cardiovascular diseases, central nervous system-related diseases, and cancer progression. Exosomes are used in two applications, which includes diagnostic and therapeutic. There are three types of products used in exosomes diagnostic and therapeutic technique, which include instrument, reagent, and software.

Key factors driving the growth of the exosome diagnostic and therapeutic market due to increase in the number of neuro-degenerative and autoimmune diseases. Rise in application of exosome diagnostic and therapeutic technique for neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, and autoimmune disorders, such as diabetes and Rheumatoid arthritis are anticipated to drive the growth of the exosome diagnostic and therapeutic market. Exosomes are nanoparticles containing bioactive molecules reflecting individual physiological status, regulating metabolism, and repairing damaged tissues. They function as biomarkers of diabetes mellitus and diabetic complications. Thus, rise in prevalence of diabetes is anticipated to fuel the application of exosomes diagnostic and therapeutic technique. Therefore, this factor is anticipated to fuel the market growth. For instance, according to International Diabetes Federation (IDF), in 2021, approximately 537 million adults in the application of 20-79 were suffering from diabetes over the globe.

Moreover, The exosome diagnostic and therapeutic posses various applications in clinical research and it is used for liquid biopsy, copy number variation (CNV), rare sequence detection, gene expression, single-cell analysis, pathogen detection, microbiome analysis, and next-generation sequencing (NGS). The increase in number of contract research organizations (CRO) and research laboratories drives the growth of market. In addition, exosome diagnostic and therapeutic are also used in diagnostic centers for the diagnosis of various infectious diseases including COVID-19 detection. The rise in number of diagnostic centers boosts the growth of market. For instance, in October 2021, government of UK announced the launch of 40 community diagnostic centers across England.

Furthermore, exosomes helps in regulating complex intracellular and extracellular vesicles, hepatocellular carcinoma pathways that are advanced in their usefulness in the therapeutic control of several neurodegenerative conditions and cancer. Thus, rise in the prevalence of cancer is anticipated to fuel the demand for exosome diagnostic and therapeutic technique, which boosts the market growth. For instance, according to American Cancer Society, in 2022, it was estimated that 1,918,030 population is suffering from cancer. As per the same source, it was estimated that, number of deaths due to cancer were 609,360 in U. S. in 2022.

The market also offers growth opportunities to the key players in the market. Rise in the number of adoptions of key strategies, such as collaboration, acquisition, partnership, agreement, and others by market players who manufacture exosome diagnostic and therapeutic is anticipated to drive the market growth. For instance, in August 2020, Aethlon Medical announced collaboration with University of Pittsburgh for the study of depleting exosome to enhance response to immune therapy in head and neck squamous cell carcinoma. Moreover, increase in the number of product launch and product approvals for exosome diagnostic and therapeutic boosts the market growth. For instance, in April 2022, Bio-Techne Corporation announced product launch of exosome diagnostics, an ExoDx for prostate cancer test at home.

The exosome diagnostic and therapeutic market is segmented on the basis of application, product, end user, and region. On the basis of application, the market is classified into diagnostic and therapeutic. On the basis of product, it is classified into instrument, reagent, and software. On the basis of end user, the market is classified into cancer institute, hospital, diagnostic center, and other.

Region wise, the market is analyzed across North America (U. S., Canada, and Mexico), Europe (Germany, UK, France, Spain, Italy, and rest of Europe), Asia-Pacific (India, China, Australia, Japan, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

The key players profiled in the study include Aethlon Medical, Inc., Bio-techne, NanoSomix Inc., Thermo Fisher Scientific Inc., Malvern Instruments Ltd., System Biosciences Inc., NX Pharmagen, Sistemic Inc., and Capricor Therapeutics, Exiqon A/S.

Key Market Insights (Updated)
By application, the diagnostic segment was the highest revenue contributor, whereas software and it is anticipated to grow at the highest CAGR of 29.5% during the forecast period
By product, the instrument segment was the highest revenue contributor, whereas software is anticipated to grow at the highest CAGR of 30.2% during the forecast period
By end user, the cancer institute segment was the highest revenue contributor, whereas diagnostic center is anticipated to grow at the highest CAGR of 30.3% during the forecast period
Based on region, North America garnered the largest revenue share in 2020, whereas Asia-Pacific is anticipated to grow at the highest CAGR of 30.3% during the forecast period

Companies Mentioned

  • Thermo Fisher Scientific, Inc.
  • Malvern Instruments Ltd
  • NX Pharmagen, Inc.
  • Sistemic Ltd
  • Exosome Diagnostic, Inc.
  • Capricor Therapeutics, Inc.
  • NanoSomix, Inc
  • System Biosciences, Inc
  • Exiqon A/S
  • Aethlon Medical, Inc.

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...